Covalent Inhibitors Allosterically Block the Activation of Rho Family Proteins and Suppress Cancer Cell Invasion. Issue 14 (13th May 2020)

• Record Type: Journal Article
• Authors: Sun, Zhongya; Zhang, Hao; Zhang, Yuanyuan; Liao, Liping; Zhou, Wen; Zhang, Fengcai; Lian, Fulin; Huang, Jing; Xu, Pan; Zhang, Rukang; Lu, Wenchao; Zhu, Mingrui; Tao, Hongru; Yang, Feng; Ding, Hong; Chen, Shijie; Yue, Liyan; Zhou, Bing; Zhang, Naixia; Tan, Minjia; Jiang, Hualiang; Chen, Kaixian; Liu, Bo; Liu, Chuanpeng; Dang, Yongjun; Luo, Cheng
• Is Part Of: Advanced science. Volume 7:Issue 14(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-05-13
• Subjects: anti‐metastasis activities -- crystal structures -- inhibitors -- novel pockets -- rho family proteins; Science -- Periodicals; 505
• DOI: 10.1002/advs.202000098
• Languages: English
• ISSNs: 2198-3844

Abstract

Abstract: The Rho family GTPases are crucial drivers of tumor growth and metastasis. However, it is difficult to develop GTPases inhibitors due to a lack of well‐characterized binding pockets for compounds. Here, through molecular dynamics simulation of the RhoA protein, a groove around cysteine 107 (Cys107) that is relatively well‐conserved within the Rho family is discovered. Using a combined strategy, the novel inhibitor DC‐Rhoin is discovered, which disrupts interaction of Rho proteins with guanine nucleotide exchange factors (GEFs) and guanine nucleotide dissociation inhibitors (GDIs). Crystallographic studies reveal that the covalent binding of DC‐Rhoin to the Cys107 residue stabilizes and captures a novel allosteric pocket. Moreover, the derivative compound DC‐Rhoin04 inhibits the migration and invasion of cancer cells, through targeting this allosteric pocket of RhoA. The study reveals a novel allosteric regulatory site within the Rho family, which can be exploited for anti‐metastasis drug development, and also provides a novel strategy for inhibitor discovery toward "undruggable" protein targets. Abstract : Covalent modification of RhoA at Cys107 by a small molecule DC‐Rhoin blocks the interaction with RhoGEF and RhoGDI. Crystallographic studies reveal that the covalent binding of DC‐Rhoin to Cys107 residue stabilizes and captures a novel allosteric pocket. Moreover, DC‐Rhoins inhibit the migration and invasion of cancer cells, through targeting Cys107 residue of RhoA in cells.